Press

Photo1 IONIQ 6 N Driving Front Quarter 1

Hyundai Motor IONIQ 6 N Debuts at Goodwood Festival of Speed, Setting New Benchmark for High-Performance EVs

Hyundai Motor Company has unveiled IONIQ 6 N, its second high-performance EV, at the iconic Goodwood Festival of Speed in West Sussex, England Building on the success of the award-winning IONIQ 5 N, IONIQ 6 N integrates cutting-edge technologies and capabilities derived from Hyundai N’s motorsport programs and ‘rolling lab’ initiatives The model embodies Hyundai […]

Hyundai Motor IONIQ 6 N Debuts at Goodwood Festival of Speed, Setting New Benchmark for High-Performance EVs Read Post »

Press
SINEXCEL Wasion Energy Power Up Landmark Energy Storage Project Central

SINEXCEL и Wasion Energy запускают знаковый проект по хранению энергии в Центральной Америке

КАРТАГО, Коста-Рика, 10 июля 2025 г. /PRNewswire/ — Система хранения энергии ветра Coopesantos, совместно разработанная SINEXCEL (300693.SZ) и Wasion Energy, официально начала свою работу в Коста-Рике. В церемонии ввода в эксплуатацию приняли участие представители муниципалитета, что стало важной вехой в сотрудничестве Китая и Коста-Рики в области возобновляемых источников энергии. Это первый проект в Центральной Америке,

SINEXCEL и Wasion Energy запускают знаковый проект по хранению энергии в Центральной Америке Read Post »

Press
SINEXCEL Wasion Energy Power Up Landmark Energy Storage Project Central

SINEXCEL und Wasion Energy treiben ein wegweisendes Energiespeicherprojekt in Mittelamerika voran

CARTAGO, Costa Rica, 10. Juli 2025 /PRNewswire/ — Das Windkraft-Energiespeichersystem Coopesantos, das gemeinsam von SINEXCEL (300693.SZ) und Wasion Energy entwickelt wurde, ist in Costa Rica offiziell in Betrieb genommen worden. An der Einweihungsfeier nahmen lokale Regierungsvertreter teil, was einen bedeutenden Meilenstein in der Zusammenarbeit zwischen China und Costa Rica im Bereich der erneuerbaren Energien darstellt.

SINEXCEL und Wasion Energy treiben ein wegweisendes Energiespeicherprojekt in Mittelamerika voran Read Post »

Press
Globee Press Logo

Call for Startup Entries Issued for the 17th Annual Globee® Awards for Innovation

Recognizing Breakthrough Ideas and Emerging Technologies from Startups Worldwide SAN FRANCISCO, July 10, 2025 /PRNewswire/ — The Globee® Awards, organizers of premier data-driven business awards programs with worldwide acceptance and industry-wide participation, have issued a call for entries for the 17th Annual Globee® Awards for Innovation, also known as the Golden Bridge Awards®. This global

Call for Startup Entries Issued for the 17th Annual Globee® Awards for Innovation Read Post »

Press

Jazz Pharmaceuticals Names Renee Gala as President and Chief Executive Officer

– Selection Follows Robust Succession Process Led by the Board – – Bruce Cozadd to Retire as CEO and Remain Chairperson of the Board of Directors – DUBLIN, July 10, 2025 /PRNewswire/ — Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Jazz Board of Directors has unanimously selected Renee Gala, Jazz’s President and Chief Operating Officer, as

Jazz Pharmaceuticals Names Renee Gala as President and Chief Executive Officer Read Post »

Press
REsides Logo

REsides Redefines MLS with Industry-Leading Subscription Tiers

New tiers offer real estate pros the choice, control, and tools they need to grow on their terms. HILTON HEAD ISLAND, S.C., July 10, 2025 /PRNewswire/ — REsides, the borderless, and tech-driven MLS, today announced the launch of its three-tiered subscription model: REsides Essential ($29.95/month), REsides Select ($80/month), and REsides Premier ($75/month). For the first time,

REsides Redefines MLS with Industry-Leading Subscription Tiers Read Post »

Press
AbbVie logo

AbbVie and Ichnos Glenmark Innovation (IGI) Announce Exclusive Global Licensing Agreement for ISB 2001, a First-in-Class CD38×BCMA×CD3 Trispecific Antibody

ISB 2001 is currently in Phase 1 clinical trial in patients with relapsed/refractory multiple myeloma (R/R MM) NORTH CHICAGO, Ill. and NEW YORK, July 10, 2025 /PRNewswire/ — AbbVie (NYSE: ABBV) and IGI Therapeutics SA, a wholly owned subsidiary of New York-based Ichnos Glenmark Innovation, Inc. (IGI), today announced an exclusive licensing agreement for IGI’s lead

AbbVie and Ichnos Glenmark Innovation (IGI) Announce Exclusive Global Licensing Agreement for ISB 2001, a First-in-Class CD38×BCMA×CD3 Trispecific Antibody Read Post »

Press
Scroll to Top